In Vitro Evaluation of NLS-DTX Activity in Triple-Negative Breast Cancer

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Aug 12

PMID 35956870

Authors

Karen L R Paiva

Marina A Radicchi

Sonia N Bao

Affiliations

Soon will be listed here.

Abstract

Cancer is one of the most lethal diseases in the world, and the development and improvement of treatments used in cancer therapies are extremely important for a better quality of life for patients. In view of the current problems in drug administration such as low solubility and adverse effects, the activity of a solid lipid nanoparticle containing docetaxel (SLN-DTX), a drug already used in conventional therapies, was evaluated in a cell line (MDA-MB-231) of one of the most aggressive types of breast cancer with the worst prognosis, triple-negative breast cancer. Viability tests indicated that SLN-DTX has a greater dependence on the treatment dose when compared to the free drug, which indicates a more controlled release of the drug, and both reduced viability by around 50% at a concentration of 1 µg/mL after 72 h. Transmission electron microscopy (TEM) and confocal and light microscopy analyses indicated that after treatment the cells enter a mitotic catastrophe, characteristic of antimitotic drugs that usually make cells progress to death or senescence. Cells treated with both DTX and SLN-DTX showed significant inhibition of mobility, 73.6% and 66.5% when treated with SLN-DTX and DTX, respectively, compared to the 11.4% of the control after 72 h, characteristics that are very relevant in tumor development and progression. SLN-DTX demonstrated its great potential as a nanocarrier by maintaining and improving the drug's action in the MDA-MB-231 cell line.

Citing Articles

Solid Lipid Nanoparticles, an Alternative for the Treatment of Triple-Negative Breast Cancer.

Llaguno-Munive M, Vazquez-Lopez M, Garcia-Lopez P Int J Mol Sci. 2024; 25(19).

PMID: 39409041 PMC: 11476567. DOI: 10.3390/ijms251910712.

Anti- Activity of Morolic Acid, a Pentacyclic Triterpene with Effects on Innate Immune Response during Macrophage Infection.

Rodrigues de Souza V, Maciel N, Machado Y, de Sousa J, Rodrigues R, Sousa Dos Santos A Microorganisms. 2024; 12(7).

PMID: 39065160 PMC: 11279160. DOI: 10.3390/microorganisms12071392.

Overview of Solid Lipid Nanoparticles in Breast Cancer Therapy.

Mo K, Kim A, Choe S, Shin M, Yoon H Pharmaceutics. 2023; 15(8).

PMID: 37631279 PMC: 10457810. DOI: 10.3390/pharmaceutics15082065.

Potential Biological Properties of Lycopene in a Self-Emulsifying Drug Delivery System.

Bao S, Machado M, Da Silva A, Melo A, Cunha S, Sousa S Molecules. 2023; 28(3).

PMID: 36770886 PMC: 9920511. DOI: 10.3390/molecules28031219.

References

Janssen A, Kops G, Medema R . Elevating the frequency of chromosome mis-segregation as a strategy to kill tumor cells. Proc Natl Acad Sci U S A. 2009; 106(45):19108-13. PMC: 2776415. DOI: 10.1073/pnas.0904343106. View

Wang E, Sinnott R, Werner M, Sethi M, Whitehurst A, Wang A . Differential cell responses to nanoparticle docetaxel and small molecule docetaxel at a sub-therapeutic dose range. Nanomedicine. 2013; 10(2):321-8. PMC: 3912219. DOI: 10.1016/j.nano.2013.07.012. View

Amreddy N, Babu A, Muralidharan R, Panneerselvam J, Srivastava A, Ahmed R . Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery. Adv Cancer Res. 2018; 137:115-170. PMC: 6550462. DOI: 10.1016/bs.acr.2017.11.003. View

Da Rocha M, da Silva P, Radicchi M, Andrade B, de Oliveira J, Venus T . Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells. J Nanobiotechnology. 2020; 18(1):43. PMC: 7068958. DOI: 10.1186/s12951-020-00604-7. View

Chen R, Ni S, Chen W, Liu M, Feng J, Hu K . Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles. Int J Nanomedicine. 2021; 16:5265-5279. PMC: 8349197. DOI: 10.2147/IJN.S313166. View

Wang W, Chen T, Xu H, Ren B, Cheng X, Qi R . Curcumin-Loaded Solid Lipid Nanoparticles Enhanced Anticancer Efficiency in Breast Cancer. Molecules. 2018; 23(7). PMC: 6099699. DOI: 10.3390/molecules23071578. View

Zhang E, Xing R, Liu S, Li P . Current advances in development of new docetaxel formulations. Expert Opin Drug Deliv. 2019; 16(3):301-312. DOI: 10.1080/17425247.2019.1583644. View

Hussain A, Oves M, Alajmi M, Hussain I, Amir S, Ahmed J . Biogenesis of ZnO nanoparticles using leaf extract: anticancer and antimicrobial activities. RSC Adv. 2022; 9(27):15357-15369. PMC: 9064228. DOI: 10.1039/c9ra01659g. View

Mukhtar E, Adhami V, Mukhtar H . Targeting microtubules by natural agents for cancer therapy. Mol Cancer Ther. 2014; 13(2):275-84. PMC: 3946048. DOI: 10.1158/1535-7163.MCT-13-0791. View

10.

Li G, Wang Y, Li L, Ren Y, Deng X, Liu J . Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities. Eur J Med Chem. 2020; 202:112519. DOI: 10.1016/j.ejmech.2020.112519. View

11.

Akanda M, Getti G, Nandi U, Mithu M, Douroumis D . Bioconjugated solid lipid nanoparticles (SLNs) for targeted prostate cancer therapy. Int J Pharm. 2021; 599:120416. DOI: 10.1016/j.ijpharm.2021.120416. View

12.

Kaushik L, Srivastava S, Panjeta A, Chaudhari D, Ghadi R, Kuche K . Exploration of docetaxel palmitate and its solid lipid nanoparticles as a novel option for alleviating the rising concern of multi-drug resistance. Int J Pharm. 2020; 578:119088. DOI: 10.1016/j.ijpharm.2020.119088. View

13.

Tischer J, Gergely F . Anti-mitotic therapies in cancer. J Cell Biol. 2018; 218(1):10-11. PMC: 6314557. DOI: 10.1083/jcb.201808077. View

14.

Li J, Zhang J, Wang Y, Liang X, Wusiman Z, Yin Y . Synergistic inhibition of migration and invasion of breast cancer cells by dual docetaxel/quercetin-loaded nanoparticles via Akt/MMP-9 pathway. Int J Pharm. 2017; 523(1):300-309. DOI: 10.1016/j.ijpharm.2017.03.040. View

15.

da Silva J, Nunes N, Izetti P, Gomes de Mesquita G, de Melo A . Triple negative breast cancer: A thorough review of biomarkers. Crit Rev Oncol Hematol. 2020; 145:102855. DOI: 10.1016/j.critrevonc.2019.102855. View

16.

Khodaverdi E, Tayarani-Najaran Z, Minbashi E, Alibolandi M, Hosseini J, Sepahi S . Docetaxel-Loaded Mixed Micelles and Polymersomes Composed of Poly (caprolactone)-Poly (ethylene glycol) (PEG-PCL) and Poly (lactic acid)-Poly (ethylene glycol) (PEG-PLA): Preparation and In-vitro Characterization. Iran J Pharm Res. 2019; 18(1):142-155. PMC: 6487438. View

17.

Zhang R, Qin X, Kong F, Chen P, Pan G . Improving cellular uptake of therapeutic entities through interaction with components of cell membrane. Drug Deliv. 2019; 26(1):328-342. PMC: 6442206. DOI: 10.1080/10717544.2019.1582730. View

18.

Sharma P . Biology and Management of Patients With Triple-Negative Breast Cancer. Oncologist. 2016; 21(9):1050-62. PMC: 5016071. DOI: 10.1634/theoncologist.2016-0067. View

19.

Singh R, Sharma G, Sonali , Singh S, Kumar M, Pandey B . Vitamin E TPGS conjugated carbon nanotubes improved efficacy of docetaxel with safety for lung cancer treatment. Colloids Surf B Biointerfaces. 2016; 141:429-442. DOI: 10.1016/j.colsurfb.2016.02.011. View

20.

Tao J, Tan Z, Diao L, Ji Z, Zhu J, Chen W . Co-delivery of dihydroartemisinin and docetaxel in pH-sensitive nanoparticles for treating metastatic breast cancer the NF-κB/MMP-2 signal pathway. RSC Adv. 2022; 8(39):21735-21744. PMC: 9080987. DOI: 10.1039/c8ra02833h. View